This international iwCLL e-learning course takes you from first principles to advanced practice in Chronic Lymphocytic Leukemia (CLL). Across five expert-led modules—Diagnosis, Basic Research, Clinical Management, Drug Development & Trials, and Patient Engagement—you’ll connect cutting-edge science with day-to-day clinical decisions and sustainable, patient-centred care.
This module presents core diagnostic technologies and analytical approaches used in the evaluation of chronic lymphocytic leukemia (CLL). It introduces key methods such as immunophenotyping, genetic assessment of TP53, immunoglobulin gene analysis, and the principles of measurable residual disease detection. Each module outlines the type of information these tools can provide and the general frameworks used to interpret their results within recognised diagnostic pathways. Together, the module offers a structured view of the technologies, analytical criteria, and interpretive concepts that contribute to the diagnostic characterisation of CLL.
This module introduces key areas of basic research that contribute to current understanding of chronic lymphocytic leukemia (CLL). It provides an outline of major scientific themes including genomic complexity, epigenetic regulation, micro-environmental interactions, and signalling processes centred on the B-cell receptor. Each module presents core concepts and research observations that shape contemporary investigations into CLL biology and disease evolution. An optional masterclass offers additional scope for participants engaged in research to examine selected developments in greater depth.
This module outlines key aspects of the clinical management of chronic lymphocytic leukemia (CLL) across the disease course. It introduces principles for the initial assessment of patients who are managed with active surveillance, approaches to frontline treatment selection, and current understanding of resistance and management in the relapsed/refractory setting. The module also highlights emerging therapeutic strategies and evolving treatment concepts. Each module presents these themes in a descriptive manner, drawing on guideline frameworks, prognostic tools and contemporary trial data, without providing prescriptive recommendations. An accompanying masterclass is designed for clinicians, nurses, pharmacists and trainees who wish to explore practical considerations in greater depth.
This lecture introduces the principles and processes that underpin clinical trial activity and therapeutic development in CLL. It outlines how trial units are organised and governed, how emerging treatments are evaluated across clinical phases, and how scientific advances in CLL contribute to wider drug development efforts. The modules describe foundational concepts including ethical and regulatory frameworks, interpretation of safety and efficacy data, and biological considerations relevant to target selection. Content is presented at a high level and is intended to complement Good Clinical Practice training completed by participants.
This module explores the role of patient engagement in strengthening and sustaining CLL services across diverse health systems. It highlights how individual patient perspectives, global advocacy networks, and structured patient and public involvement contribute to improved equity, access, research relevance and service design. The modules draw on international initiatives, real-world examples and best-practice frameworks to illustrate how patient voices shape awareness, policy, research and resource development. Themes include lived experience, formation of patient organisations, co-production in research, and the specific barriers faced in low- and middle-income countries (LMICs) when accessing diagnostics and treatment. All content is presented descriptively, focusing on conceptual understanding rather than prescribing models of care.